Bioinformatics Identification of Therapeutic Gene Targets for Gastric Cancer
- 24 January 2023
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (4) , 1456-1473
Abstract
Introduction The global prevalence of gastric cancer (GC) is increasing, and novel chemotherapeutic targets are needed. Methods We searched for potential biomarkers for GC in three microarray data sets within the Gene Expression Omnibus (GEO) database. FunRich (v3.1.3) was used to perform Gene Ontology (GO) analyses and STRUN and Cytoscape (v3.6.0) were employed to construct a protein–protein interaction (PPI) network. To explore hub gene expression and survival, we used Gene Expression Profiling Interactive Analysis (GEPIA) and Kaplan–Meier (KM) plotter. Drugs that were closely related to key genes were screened by the Gene Set Cancer Analysis (GSCA), and relevant correlations were verified experimentally. We validated that the sensitivity of a GC cell line to these drugs was correlated with fibrillin 1 (FBN1) mRNA expression levels. Results We identified 83 upregulated and 133 downregulated differentially expressed genes (DEGs) and these were enriched with regards to their cellular component (extracellular and exosomes), molecular function (extracellular matrix structural constituent and catalytic activity), and biological process (cell growth and/or maintenance and metabolism). The biological pathways most prominently involved were epithelial-to-mesenchymal transition (EMT) and β3 integrin cell surface interactions. For the PPI network, we selected 10 hub genes, and 70% of these were significantly connected to poor overall survival (OS) in patients with GC. We found a significant link between the expression of FBN1 and two small molecule drugs (PAC-1 and PHA-793887). Conclusions Overall, we suggest that these hub genes can be used as biomarkers and novel targets for GC. FBN1 may be associated with drug resistance in gastric cancer.Keywords
Funding Information
- National Natural Science Foundation of China (81903660)
- Sichuan Science and Technology Plan Project (2019YJ0386)
- Nanchong City and School Cooperation Project (19SXHZ0201, 20SXQT0101)
- Affiliated Hospital of North Sichuan Medical College Plan Projects (2021YS009, 2022JB006)
This publication has 54 references indexed in Scilit:
- Structure of the Fibrillin-1 N-Terminal Domains Suggests that Heparan Sulfate Regulates the Early Stages of Microfibril AssemblyStructure, 2013
- NCBI GEO: archive for functional genomics data sets—updateNucleic Acids Research, 2012
- A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumorsCell Cycle, 2011
- An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpes viridaeCell Cycle, 2011
- mRNA transcripts as molecular biomarkers in medicine and nutritionThe Journal of Nutritional Biochemistry, 2010
- Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosingBioorganic & Medicinal Chemistry, 2010
- Procaspase-3 Activation as an Anti-Cancer Strategy: Structure−Activity Relationship of Procaspase-Activating Compound 1 (PAC-1) and Its Cellular Co-Localization with Caspase-3Journal of Medicinal Chemistry, 2009
- Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosisMolecular Oncology, 2007
- Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategyNature Chemical Biology, 2006
- Fibrillin expression and localization in various types of carcinomas of the thyroid glandLaboratory Investigation, 2006